Jefferies Group LLC Ligand Pharmaceuticals Inc Transaction History

Jefferies Group LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$102.33 - $144.73 $1.87 Million - $2.64 Million	-18,250 Reduced 38.88%	28,688 $4 Million
Q2 2021 Sep 21, 2023	BUY	$113.03 - $155.64 $2.65 Million - $3.65 Million	23,469 New	23,469 $3.08 Million
Q2 2021 Aug 16, 2021	BUY	$113.03 - $155.64 $5.31 Million - $7.31 Million	46,938 New	46,938 $6.16 Million
Q4 2020 Feb 16, 2021	SELL	$80.55 - $106.05 $229,406 - $302,030	-2,848 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$89.56 - $126.72 $255,066 - $360,898	2,848 New	2,848 $271,000
Q2 2019 Aug 14, 2019	SELL	$107.38 - $129.34 $548,174 - $660,280	-5,105 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$105.93 - $142.47 $231,139 - $310,869	2,182 Added 74.65%	5,105 $642,000
Q4 2018 Feb 14, 2019	SELL	$128.36 - $272.13 $1.97 Million - $4.19 Million	-15,383 Reduced 84.03%	2,923 $397,000
Q3 2018 Nov 14, 2018	SELL	$211.18 - $274.49 $5.69 Million - $7.39 Million	-26,936 Reduced 59.54%	18,306 $5.03 Million
Q2 2018 Aug 14, 2018	BUY	$150.77 - $207.98 $6.82 Million - $9.41 Million	45,242 New	45,242 $9.37 Million

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.88B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.